Free Trial

Bio-Techne (TECH) Stock Price, News & Analysis

+0.18 (+0.22%)
(As of 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
823,402 shs
Average Volume
1.11 million shs
Market Capitalization
$13.03 billion
P/E Ratio
Dividend Yield
Price Target

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
2.6% Downside
$80.50 Price Target
Short Interest
3.76% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
1.25mentions of Bio-Techne in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$800,592 Sold Last Quarter
Proj. Earnings Growth
From $1.56 to $1.81 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.24 out of 5 stars

Medical Sector

158th out of 921 stocks

Biological Products, Except Diagnostic Industry

19th out of 151 stocks

TECH stock logo

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

TECH Stock News Headlines

Bio-Techne Corp (TE1.SG)
Bio-Techne Corp. Q3 Profit Decreases, but beats estimates
Bio-Techne earnings preview: what Wall Street is expecting
Bio-Techne In Distribution Agreement With Thermo Fisher Scientific
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/26 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 5/24 Dividend
Dividend Payable
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Biological products, except diagnostic
Life Sciences Tools & Services
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
11 Analysts


Net Income
$285.26 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.50 per share
Book Value
$12.49 per share


Free Float
Market Cap
$13.11 billion

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price target for 2024?

11 Wall Street analysts have issued 12-month price objectives for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $95.00. On average, they predict the company's stock price to reach $80.50 in the next year. This suggests that the stock has a possible downside of 2.6%.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2024?

Bio-Techne's stock was trading at $77.16 at the start of the year. Since then, TECH shares have increased by 7.2% and is now trading at $82.68.
View the best growth stocks for 2024 here

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our TECH earnings forecast

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The biotechnology company earned $303.43 million during the quarter, compared to analyst estimates of $292.36 million. Bio-Techne had a net margin of 17.59% and a trailing twelve-month return on equity of 13.60%. The firm's revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.47 EPS.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Wednesday, May 1st. Stockholders of record on Monday, May 13th will be paid a dividend of $0.08 per share on Friday, May 24th. This represents a $0.32 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, May 10th.
Read our dividend analysis for TECH

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.38%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 25.40%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 17.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Shares of Bio-Techne split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were payable to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.62%), Price T Rowe Associates Inc. MD (3.65%), Bamco Inc. NY (3.17%), Bank of New York Mellon Corp (1.82%), Champlain Investment Partners LLC (1.74%) and Brown Capital Management LLC (1.63%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
This page (NASDAQ:TECH) was last updated on 5/21/2024 by Staff

From Our Partners